A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm
- 1 March 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Pain
- Vol. 85 (1) , 101-105
- https://doi.org/10.1016/s0304-3959(99)00264-x
Abstract
Myofascial pain syndrome (MPS) is a common illness, characterised by acute or chronic focal pain, muscle stiffness and fatigue. The pathophysiology of MPS remains unclear. Previous preliminary studies have demonstrated therapeutic efficacy of the muscle relaxant botulinum toxin type A (BTX-AKeywords
This publication has 11 references indexed in Scilit:
- New Developments in Diagnosis of Myofascial Pain and FibromyalgiaPhysical Medicine and Rehabilitation Clinics of North America, 1997
- Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injectionMuscle & Nerve, 1996
- Molecular aspects of tetanus and botulinum neurotoxin poisoningProgress in Neurobiology, 1995
- Superficial Dry Needling at Myofascial Trigger Point SitesJournal of Musculoskeletal Pain, 1995
- Botulinum toxin in the treatment of myofascial pain syndromePain, 1994
- Referred pain of Peripheral Nerve OriginThe Clinical Journal of Pain, 1994
- Treatment of Myofascial Pain with Botulinum A ToxinAnesthesiology, 1994
- Myofascial Trigger Points Show Spontaneous Needle EMG ActivitySpine, 1993
- Botulinum a Toxin Effects on Rat Jaw Muscle SpindlesActa Oto-Laryngologica, 1993
- Analgesic-Associated NephropathyNew England Journal of Medicine, 1978